ClinicalTrials.gg
CompletedNCT02620046Updated Apr 3, 2025Results posted

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

A Phase 3 interventional study of Vedolizumab SC in Colitis, Ulcerative and Crohn's Disease, sponsored by Takeda. Completed at 301 sites in 33 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
746
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
5th of 38
746 · median 110
Started
2016
with 2 others
Phase 3
14 of 38
3 open now
Registered
9th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 5th largest by enrollment, is one of 3 that started in 2016, is one of 14 in phase 3, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD). Vedolizumab SC will be given as an injection just under the skin. This type of injection is called a subcutaneous injection or SC for short. Another aim of the study is to collect information on whether the participant's condition remains under control or improves during and after treatment with Vedolizumab SC.

Participants who previously took part in studies MLN0002SC-3027 or MLN0002SC-3031 will be invited to visit the study clinic. At this visit, the study doctor will check if each participant can take part in this study.

For those who can take part, participants will receive a subcutaneous injection of vedolizumab SC either once a week or once every 2 weeks. How often each participant receives vedolizumab SC will depend on their results from the previous study and on how active their condition is. Participants might be able to self-inject vedolizumab SC after being trained by the study doctors. During this study, the dose of vedolizumab SC might be increased for participants whose condition worsens.

Participants will continue treatment with vedolizumab SC until it is approved in their particular country, the participant decides to stop treatment, or the sponsor stops the study. If the sponsor stops the study before vedolizumab SC is approved in all countries, the sponsor will make sure all affected participants will have access to vedolizumab SC outside of the study.

After their final dose of vedolizumab SC, participants will visit the clinic 18 weeks later for a final check-up. Then, the clinic will telephone the participants 6 months after their final dose of vedolizumab SC to check if they have any health problems.

Read the detailed description

The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to assess its long-term safety and effectiveness in treating participants with UC or CD. This study will look at the long-term side effects and response/remission of UC and CD in participants who received vedolizumab SC in a prior vedolizumab SC study.

The study will enroll up to 692 patients. All participants enrolled in this study will have previously participated in the MLN0002SC-3027 or MLN0002SC-3031 study. Participants who completed the Maintenance Period (Week 52) in their previous study, or who did not achieve a clinical response at Week 6 but who did achieve a clinical response at Week 14 after having received a third vedolizumab IV infusion at Week 6 in their previous study, will receive open-label vedolizumab SC 108 mg, once every 2 weeks (Q2W). Participants who withdrew early from the Maintenance Period of their previous study due to disease worsening or need for rescue medications will receive open-label vedolizumab SC 108 mg, once every week (QW). Participants receiving SC 108 mg Q2W who experience treatment failure (disease worsening or need for rescue medications while in the current study will be dose escalated to vedolizumab SC 108 mg QW.

This multi-center trial will be conducted worldwide. Participation in this vedolizumab SC study will continue until vedolizumab SC becomes commercially available, the participant withdraws from the study, or the sponsor decides to close the study. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn's Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior participation in Study MLN0002SC-3027 or MLN0002SC-3031, and, in the opinion of the investigator, tolerated the study drug well. Early withdrawal from Study MLN0002SC-3027 or MLN0002SC-3031 must have been due to treatment failure during the Maintenance Period.

Exclusion criteria

Exclusion Criteria:

  1. Surgical intervention for IBD during or after participation in Study MLN0002SC-3027 or MLN0002SC-3031, or at any time during this study.
  2. Chronic or severe infection, or, any new, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurologic, oncologic, or other medical disorder developed during or after participation in a prior vedolizumab study that, in the opinion of the investigator, would confound the study results or compromise participant safety.
  3. Withdrawal from Study MLN0002SC-3027 or MLN0002SC-3031 due to a study-drug related adverse event (AE).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
746 participants (actual)

Study arms

  • Experimental
    Ulcerative Colitis: Vedolizumab 108 mg

    Participants with ulcerative colitis (UC) who completed the Maintenance Phase in MLN0002SC-3027 (Week 52 assessment) or who did not achieve a clinical response at Week 6 in MLN0002SC-3027 but who did achieve a clinical response at Week 14 of the parent study after having received a third vedolizumab IV infusion at Week 6 in the parent study received vedolizumab SC 108 mg Q2W in this study whereas who withdrew early from the Maintenance Phase (at Week 14 onwards) in MLN0002SC-3027 due to disease worsening or need for rescue medications received vedolizumab SC 108 mg QW.

    Drug: Vedolizumab SC

  • Experimental
    Crohn's Disease: Vedolizumab 108 mg

    Participants with Crohn's disease (CD) who completed the Maintenance Phase in MLN0002SC-3031 (Week 52 assessment) or who did not achieve a clinical response at Week 6 in MLN0002SC-3031 but who did achieve a clinical response at Week 14 of the parent study after having received a third vedolizumab IV infusion at Week 6 in the parent study received vedolizumab SC 108 mg Q2W in this study whereas who withdrew early from the Maintenance Phase (at Week 14 onwards) in MLN0002SC-3031 due to disease worsening or need for rescue medications received vedolizumab SC 108 mg QW.

    Drug: Vedolizumab SC

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment

    A TEAE was defined as an adverse event (AE) that started or worsened on or after study Day 1 (defined as day first dosed) and no more than 18 weeks after the last dose of study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose and resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event such as acute liver failure, pulmonary hypertension, or confirmed or suspected transmission of an infectious agent by a medicinal product. Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.

    Time frame: Up to 97.9 months

Secondary outcomes

  1. Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment

    AESIs included hypersensitivity reactions (including injections site reactions), serious infections, malignancies, hepatotoxicity (abnormal liver function test) and progressive multifocal leukoencephalopathy (PML). Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.

    Time frame: Up to 97.9 months

  2. Number of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48

    Clinical response is defined as a decrease in the partial Mayo score of at least 2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point from baseline or absolute rectal bleeding subscore of ≤1 point. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.

    Time frame: Week 48

  3. Number of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 48

    Clinical response is defined as a decrease in HBI score of ≥3 points from baseline in CD participants (randomized early terminator CD participants only \[defined as randomized CD participants withdrawn from the parent study between Week 6 and Week 52\]). As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.

    Time frame: Week 48

  4. Number of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score

    Clinical remission is defined as a partial Mayo score of ≤2 with no individual subscore \>1. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.

    Time frame: Week 48

  5. Number of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores

    Clinical remission is defined as total HBI score of ≤4 points. As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.

    Time frame: Week 48

07

Results

Posted Apr 3, 2025

Participant flow

Participants took part in the study at various investigative sites globally from 15 April 2016 to 12 June 2024.

Participant flow — Overall Study
MilestoneUlcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mg
Started288458
Completed125162
Not completed163296
Withdrew: Adverse event2242
Withdrew: Lost to follow-up410
Withdrew: Withdrawal by subject3666
Withdrew: Site termination33
Withdrew: Pregnancy37
Withdrew: Lack of efficacy81146
Withdrew: Leukopenia or lymphopenia10
Withdrew: Reason not specified1321
Withdrew: Significant protocol deviation01

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment

A TEAE was defined as an adverse event (AE) that started or worsened on or after study Day 1 (defined as day first dosed) and no more than 18 weeks after the last dose of study drug. An SAE was defined as any untoward medical occurrence that occurs at any dose and resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event such as acute liver failure, pulmonary hypertension, or confirmed or suspected transmission of an infectious agent by a medicinal product. Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.

Time frame:
Up to 97.9 months
Reported as:
Number · events per 100 participant years
Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
events per 100 participant yearsUlcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mg
TEAEs22.928.0
Serious TEAEs6.58.7
SecondaryNumber of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment

AESIs included hypersensitivity reactions (including injections site reactions), serious infections, malignancies, hepatotoxicity (abnormal liver function test) and progressive multifocal leukoencephalopathy (PML). Participant years is defined as the total exposure-time of the participants in the respective treatment group. Incidence per 100 participant years is defined as (Number of participants with events\*100/participant years). As per planned analysis, data for this outcome measure is grouped and presented per disease condition.

Time frame:
Up to 97.9 months
Reported as:
Number · events per 100 participant years
Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
events per 100 participant yearsUlcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mg
Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment16.317.4
SecondaryNumber of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48

Clinical response is defined as a decrease in the partial Mayo score of at least 2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point from baseline or absolute rectal bleeding subscore of ≤1 point. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48
ParticipantsUlcerative Colitis: Vedolizumab 108 mg
Number of Participants With Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response at Week 48168
SecondaryNumber of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 48

Clinical response is defined as a decrease in HBI score of ≥3 points from baseline in CD participants (randomized early terminator CD participants only \[defined as randomized CD participants withdrawn from the parent study between Week 6 and Week 52\]). As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 48
ParticipantsCrohn's Disease: Vedolizumab 108 mg
Number of Participants With Crohn's Disease Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) Scores at Week 4832
SecondaryNumber of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score

Clinical remission is defined as a partial Mayo score of ≤2 with no individual subscore \>1. As per planned analysis, data for this outcome measure is grouped and presented for participants with ulcerative colitis.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score
ParticipantsUlcerative Colitis: Vedolizumab 108 mg
Number of Participants With Ulcerative Colitis Achieving Clinical Remission Based on Partial Mayo Score150
SecondaryNumber of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores

Clinical remission is defined as total HBI score of ≤4 points. As per planned analysis, data for this outcome measure is grouped and presented for participants with Crohn's disease.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores
ParticipantsCrohn's Disease: Vedolizumab 108 mg
Number of Participants With Crohn's Disease Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) Scores217

Adverse events

Collected over Up to 97.9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ulcerative Colitis: Only Vedolizumab Q2W3/163 (1.8%)29/163 (17.8%)94/163 (57.7%)
Ulcerative Colitis: Only Vedolizumab QW0/60 (0%)12/60 (20%)41/60 (68.3%)
Ulcerative Colitis: Vedolizumab Dose Escalation From Q2W to QW0/65 (0%)24/65 (36.9%)55/65 (84.6%)
Crohn's Disease: Only Vedolizumab Q2W2/239 (0.8%)55/239 (23%)151/239 (63.2%)
Crohn's Disease: Only Vedolizumab QW0/117 (0%)35/117 (29.9%)78/117 (66.7%)
Crohn's Disease: Vedolizumab Dose Escalation From Q2W to QW0/102 (0%)31/102 (30.4%)90/102 (88.2%)
Most frequent serious events
Showing 10 of 151
Most frequent serious events
EventUlcerative Colitis: Only Vedolizumab Q2WUlcerative Colitis: Only Vedolizumab QWUlcerative Colitis: Vedolizumab Dose Escalation From Q2W to QWCrohn's Disease: Only Vedolizumab Q2WCrohn's Disease: Only Vedolizumab QWCrohn's Disease: Vedolizumab Dose Escalation From Q2W to QW
Colitis ulcerativeGastrointestinal disorders4/1637/6011/650/2390/1170/102
Crohn's diseaseGastrointestinal disorders0/1630/600/654/23910/11714/102
AnaemiaBlood and lymphatic system disorders3/1631/606/653/2393/1170/102
Acute kidney injuryRenal and urinary disorders0/1630/602/651/2390/1170/102
Muscular weaknessMusculoskeletal and connective tissue disorders0/1630/602/650/2390/1170/102
PneumoniaInfections and infestations0/1630/600/651/2391/1173/102
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/610/270/320/1060/631/45
Small intestinal obstructionGastrointestinal disorders0/1630/600/655/2391/1171/102
ArthralgiaMusculoskeletal and connective tissue disorders0/1630/601/650/2392/1170/102
DiarrhoeaGastrointestinal disorders0/1630/600/650/2392/1170/102
Most frequent other events
Showing 10 of 32
Most frequent other events
EventUlcerative Colitis: Only Vedolizumab Q2WUlcerative Colitis: Only Vedolizumab QWUlcerative Colitis: Vedolizumab Dose Escalation From Q2W to QWCrohn's Disease: Only Vedolizumab Q2WCrohn's Disease: Only Vedolizumab QWCrohn's Disease: Vedolizumab Dose Escalation From Q2W to QW
Crohn's diseaseGastrointestinal disorders1/1630/600/6526/23930/11753/102
Colitis ulcerativeGastrointestinal disorders8/16314/6033/650/2390/1170/102
NasopharyngitisInfections and infestations23/16311/6015/6526/23916/11720/102
Upper respiratory tract infectionInfections and infestations28/1636/607/6538/23913/11718/102
Abdominal painGastrointestinal disorders8/1633/602/6533/23920/11715/102
COVID-19Infections and infestations24/1632/605/6529/2394/1179/102
ArthralgiaMusculoskeletal and connective tissue disorders8/1633/605/6534/23914/11711/102
AnaemiaBlood and lymphatic system disorders3/1635/609/6514/2393/1176/102
HeadacheNervous system disorders8/1633/607/6519/2395/11714/102
NauseaGastrointestinal disorders7/1631/603/6514/2397/11713/102

Baseline characteristics

The Safety Analysis Set (SAF) included all participants who had received at least 1 dose of study medication in this study (MLN0002SC-3030). As per planned analysis, baseline characteristics data was collected and presented per disease condition in the arm groups, 'Ulcerative Colitis: Vedolizumab 108 mg' and 'Crohn's Disease: Vedolizumab 108 mg'.

Age, Categorical
Age, Categorical(Participants)Ulcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mgTotal
<=18 years000
Between 18 and 65 years265440705
>=65 years231841
Sex: Female, Male
Sex: Female, Male(Participants)Ulcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mgTotal
Female120214334
Male168244412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ulcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mgTotal
Hispanic or Latino134
Not Hispanic or Latino3494128
Unknown or Not Reported253361614
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ulcerative Colitis: Vedolizumab 108 mgCrohn's Disease: Vedolizumab 108 mgTotal
American Indian or Alaska Native224
Asian582886
Native Hawaiian or Other Pacific Islander011
Black or African American2911
White226417643
More than one race011
Unknown or Not Reported000
08

Study locations

301 sites
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 85307, United States
  • Arkansas Primary Care Clinic, PA
    Little Rock, Arkansas 72204, United States
  • Rocky Mountain Clinical Research, LLC
    Wheat Ridge, Colorado 80033, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Middlesex Gastroenterology Associates
    Middletown, Connecticut 06457, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 34452, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • L & L Research Choices, Inc.
    Miami, Florida 33176, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • BRCR Medical Center, Inc.
    Pembroke Pines, Florida 33028, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Grand Teton Research Group, PLL
    Idaho Falls, Idaho 83404, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Tri-State Gastroenterology Associates
    Crestview Hills, Kentucky 41017, United States
  • Research Concierge, LLC
    Owensboro, Kentucky 42303, United States
  • Gastroenterology Associates, LLC
    Baton Rouge, Louisiana 70809, United States
  • Lafayette General Medical Center
    Lafayette, Louisiana 70503, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71103, United States
  • Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Digestive Health Center PA
    Ocean Springs, Mississippi 39564, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 64012, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • Gastro-Enterology Research of Lima
    Lima, Ohio 45806, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • Main Line Gastroenterology Associates
    Perkasie, Pennsylvania 18944, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Gastroenterology Center of the MidSouth PC
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • San Antonio Gastroenterology
    San Antonio, Texas 78212, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • Virginia Mason Seattle Main Clinic
    Seattle, Washington 98101, United States
  • Allegiance Research Specialists, LLC
    Milwaukee, Wisconsin 53226, United States
  • Hospital Italiano
    Ciudad Autonoma Buenos Aires, Buenos Aires C1181ACH, Argentina
  • Centro de Investigaciones Medicas Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • Centro Medico Viamonte SRL
    Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires C1120AAC, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Tennyson Centre Day Hospital
    Kurralta Park, South Australia 5037, Australia
  • Ballarat Base Hospital
    Ballarat, Victoria 3350, Australia
  • Monash Medical Centre Clayton
    Bentleigh East, Victoria 3165, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • St Frances Xavier Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • AZ Sint-Lucas
    Brugge, 8310, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • AZ Groeninge - Kennedylaan
    Kortrijk, 8500, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • Clinique Saint-Pierre
    Ottignies, 1340, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • University Clinical Hospital Mostar
    Mostar, 88000, Bosnia and Herzegovina
  • Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda
    Goiania, Goias 74535-170, Brazil
  • HUGG - Hospital Universitario Gaffree e Guinle
    Rio de Janeiro, Rio Do Janeiro 20270-004, Brazil
  • HUCFF-UFRJ - Hospital Universitario Clementino Fraga Filho - Universidade Federal do Rio de Janeiro
    Rio de Janeiro, Rio Do Janeiro 21941-913, Brazil
  • Hospital Sao Vicente de Paulo
    Passo Fundo, Rio Grande Do Sul 99010-080, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, Sao Paulo 18618-970, Brazil
  • Faculdade de Medicina do ABC
    Santo Andre, Sao Paulo 09060-650, Brazil
  • Irmandade da Santa Casa da Misericordia de Santos
    Santos, Sao Paulo 11075-900, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil
  • "MHAT Avis - Medica" OOD
    Pleven, 5800, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • MHAT - Silistra AD
    Silistra, 7500, Bulgaria
  • MC "Tsaritsa Yoanna' EOOD
    Sliven, 8800, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • Second MHAT - Sofia AD
    Sofia, 1202, Bulgaria
  • "City Clinic UMHAC" EOOD
    Sofia, 1407, Bulgaria
  • Medical Center "Excelsior", OOD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • UMHAT 'Tsaritsa Yoanna - ISUL', EAD
    Sofia, 1527, Bulgaria
  • Fourth MHAT - Sofia EAD
    Sofia, 1606, Bulgaria
  • Military Medical Academy - MHAT - Sofia
    Sofia, 1606, Bulgaria
  • UMHAT 'Sveta Anna' AD
    Sofia, 1750, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • Zeidler Ledcor Centre - University of Alberta
    Edmonton, Alberta T6G 2X8, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, British Columbia V8V 3M9, Canada
  • LHSC - University Hospital
    London, Ontario N6A 5A5, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada

Showing the first 100 of 301 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jun 2024, 97 months.

Results were first posted in Apr 2025, 9 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 97 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Dec 2, 2015
StartActual
Apr 15, 2016
Primary completionActual
Jun 12, 2024
CompletionActual
Jun 12, 2024
Results first posted
Apr 3, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02620046
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 2, 2015
Start date
Apr 15, 2016
Primary completion
Jun 12, 2024
Completion
Jun 12, 2024
Results posted
Apr 3, 2025
Last update
Apr 3, 2025

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion